fda glp-1 warning october 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of US FDA warns 30 telehealth

SA-SIBS Scholarship Program (L.H.Z

Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist

As a 2026 review noted, the original composition-of-matter patents "have likely expired reducing the commercial exclusivity that typically incentivizes industry-sponsored Phase II and III development" [13]

Having a sterile, sealed, empty vial on hand is good practice

If youre unsure whether an expense qualifies, check with your HSA or FSA administrator before you spend the money

Repeated use of D51.9 without progression to a specific code signals incomplete workup and reduces reimbursement